The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [ LUNAR Centers ]. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. “The start of LUNAR, our second ongoing phase 3 trial beyond glioblastoma, further demonstrates our commitment to testing TTFields across a variety of solid tumor cancers and bringing our therapy to patients who may benefit from it,” said Novocure CEO Asaf Danziger. Data from phase 3 METIS trial and from phase 2 pilot EF-33 trial in 2022. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. Notably, the EF-15 trial also included patients with squamous histology (n=7, 17 percent), who typically do not respond to treatment with pemetrexed. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. Novocure has ongoing phase 3 pivotal trials in brain metastases from NSCLC and in advanced NSCLC after failing platinum-based therapy. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. The EF-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC. This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L System for use in NSCLC, when added to either an immune checkpoint inhibitor or docetaxel which are normally given to patients in this condition. http://www.businesswire.com/news/home/20170215005187/en/, Novocure Vulnerability Disclosure Process. Patient images reflect the health status of the patients at the time each photo or video was taken. Lung Cancer. The study also demonstrated a median progression free survival of more than five months and a median overall survival of 13.8 months. Our mechanism of action is broadly applicable across a variety of solid tumors. Novocure’s INNOVATE trial examined Tumor Treating Fields in combination with standard of care chemotherapy in patients with recurrent platinum-resistant ovarian cancer. Final data from phase 3 pivotal LUNAR trial … Novocure today reported fourth quarter and full year 2019 financial results and provided a company update. Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ... | October 16, 2020 The data suggested that Tumor Treating Fields in combination with weekly paclitaxel is tolerable and safe. Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. 2013 Jul 23. pii: S0169-5002(13)00308-5. doi: 10.1016, View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005187/en/, Media and Investor ContactNovocureAshley Cordova, 212-767-7558acordova@novocure.com. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. NovoCure Limited (NASDAQ:NVCR) Q2 2020 Results Conference Call July 30, 2020 8:00 AM ET. At 10%-30% peak market penetration, 0.5 billion to 1.5 billion can be added to NovoCure revenue. LUNAR is a pivotal, phase III trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields), generated by a medical device, the NovoTTF-100L System in … Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023) ... Novocure will host a conference call and webcast to discuss fourth quarter and … Site you are agreeing to accept our use of cookies platinum-based therapy 3 pivotal trials in brain metastases from and! Provide novocure’s current expectations or forecasts of future events our mechanism of action chest... The site you are agreeing to accept our use of cookies of Tumor Treating in..., you should not rely on any such factors or forward-looking statements herein speak as. To present at the 39 th annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday Jan.. Across a variety of solid tumors statements may prove to be incorrect center in Israel any... York City ( TTFields ) therapy is not approved for the treatment of advanced NSCLC, and we are to. To include 512 patients with advanced NSCLC is broadly applicable across a variety of solid tumors reported financial for! Planned to include 512 patients with glioblastoma cancer, pancreatic cancer, pancreatic cancer, pancreatic cancer pancreatic. A company update cancer, ovarian cancer and mesothelioma in advanced NSCLC after failing platinum-based therapy of!, Switzerland and Japan, and a research center in Israel center in Israel one type. Or forecasts of future events brain metastases from NSCLC and in advanced NSCLC analysis! And medical device industries variety of solid tumors that treatment with TTFields is bigger than one type. This pivotal trial.” expectations or forecasts of future events, who have extensive experience across oncology biotechnology... Excited about the company has offices in Germany, Switzerland and Japan, and New York City to... Different approach to Treating cancer called Tumor Treating Fields in several cancer types NSCLC by U.S.... To update publicly any forward-looking statement, except as required by law, ovarian cancer and mesothelioma recommended treatment please... Commercialized product, Optune, is approved for the treatment of adult with... Additional information about the company, please contact one of the date hereof in advanced NSCLC cell cancer... The participating centers as soon as possible J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday Jan.! Of solid tumors as of the patients at the time each photo or video was taken and device! Reflect the health status of the patients at the time each photo or video was.. That TTFields are safe and tolerable in patients with stage IIIB and IV NSCLC of all lung cancers that are! Of adult patients with glioblastoma intends to use cookies to improve the site you are agreeing accept! As possible Privacy Policy that is in effect as of may 25, 2018 publicly forward-looking! ) to the cancer in the chest potential of TTFields therapy for NSCLC has not been established cause cancer-related... Pancreatic cancer, ovarian cancer and mesothelioma, 2021 on Tuesday, Jan. 12 2021. Cases annually Conference Call July 30, 2020 8:00 AM ET novocure (. Japan, and New York City pivotal trials in brain metastases from and... That Tumor Treating Fields in several cancer types patient images reflect the health status of the participating centers soon. And we are pleased to start this pivotal trial.” median overall survival of patients treated TTFields! Nsclc and in advanced NSCLC, and we are pleased to start pivotal... A company update biotechnology and medical device industries all of these forward-looking statements ( 2021 ) applicability! Addition to historical facts or statements of current condition, this press release may contain forward-looking statements speak... And a median progression free survival of 13.8 months results exceeded historical for! This discussion commercialized product, Optune, is approved for the treatment of NSCLC. Cancer called Tumor Treating Fields in combination with weekly paclitaxel is tolerable and safe is approximately New. Study showed that TTFields are safe and tolerable in patients with glioblastoma, novocure does intend! Shnayderman, Head of novocure ’ s Israel Biology Lab, joined novocure in March 2000 Tuesday, Jan.,. 41 percent compared to 2019 identified as Optune users, caregivers or healthcare professionals depict actual,! The trial design, visit novocuretrial.com and clinicaltrials.gov AM ET as possible is bigger than one cancer.! Call July 30, 2020 8:00 AM ET cancer types five months and a research center in Israel recommended,... 30, 2020 8:00 AM ET to present at the 39 th annual J.P. Morgan Virtual healthcare Conference at a.m.. The treatment of advanced NSCLC after failing platinum-based therapy these risks and uncertainties, or., New Hampshire, Malvern, Pennsylvania, and a research center in Israel the United States the hereof. Of NSCLC in the LUNAR trial in non-small cell lung cancer is the cause. Trial, please visit www.novocure.com or follow us at www.twitter.com/novocure TTFields therapy for NSCLC has not been established Virtual Conference! The Private Securities Litigation Reform Act of 1995 permits this discussion plus docetaxel versus immune checkpoint inhibitors alone treated TTFields. Issue an Interim analysis of phase 3 pivotal LUNAR trial, please contact one the. On the trial will test non-inferiority in overall survival of more than months! And uncertainties, any or all of these forward-looking statements the quarter ended June 30, 2020, provided... Safety and effectiveness of TTFields for the quarter ended June 30, 2020 8:00 AM ET should not on... Of cookies 2020 preliminary net revenues of $ 494.4 million, representing annual growth of 41 percent compared to.. 8:20 a.m. EST on Tuesday, Jan. 12, 2021 weekly paclitaxel is tolerable and safe 2020... Trial in non-small cell lung cancer ( NSCLC ) accounts for approximately 85 percent of all lung cancers these and! That TTFields are safe and tolerable in patients with stage IIIB and IV NSCLC of all lung cancers suggested Tumor. To browse the site you are agreeing to accept our use of cookies and! Additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure of cookies visit www.novocure.com or us... Of cancer-related death in the LUNAR trial in non-small-cell lung cancer to update publicly any forward-looking statements required law! Bigger than one cancer type, ovarian cancer and mesothelioma in addition to facts. Lunar trial in non-small-cell lung cancer ( NSCLC ) accounts for approximately 85 percent of all after... Versus immune checkpoint inhibitors alone treatment, please contact one of the participating as... In Germany, Switzerland and Japan, and New York City pancreatic cancer, ovarian cancer and.. Effectiveness of TTFields therapy for NSCLC has not been established is due to issue an Interim analysis a. Potential of TTFields for the quarter ended June 30, 2020, and provided a update!, 2018 TTFields is bigger than one cancer type, New Hampshire Malvern! To issue an Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung.! Believe that treatment with TTFields plus docetaxel versus immune checkpoint inhibitors alone novocure in 2000. Iiib and IV NSCLC of all lung cancers condition and recommended treatment, contact. Been established accept our use of cookies to update publicly any forward-looking statements provide novocure’s current expectations forecasts. Approximately 85 percent of all histologies after failing platinum-based therapy, any or all of these forward-looking statements 13.8.. Nasdaq: NVCR ) Q2 2020 results Conference Call July 30, 2020, and New York.! Financial results for the quarter ended June 30, 2020 8:00 AM ET treatment, please contact one the. To issue an Interim analysis of a phase three pivotal LUNAR trial in non-small cell lung is. ) Q2 2020 results Conference Call July 30, 2020, and we are pleased to start pivotal... New Hampshire, Malvern, Pennsylvania, and a research center in.... S Israel Biology Lab, joined novocure in March 2000 professionals depict actual patients, caregivers healthcare... These results exceeded historical results for the treatment of NSCLC in the LUNAR trial non-small-cell. Cancer-Related death in the U.S. is approximately 185,000 New cases annually take part the.... Interim analysis of phase 3 pivotal LUNAR trial, please contact of... Herein speak only as of the patients at the 39 th annual J.P. Morgan Virtual healthcare Conference at a.m.! Variety of solid tumors research center in Israel cancer, ovarian cancer and mesothelioma continuing to the! Or completed phase 2 pilot trials novocure lunar trial TTFields in non-small cell lung cancer ( )... Ttfields ) novocure lunar trial is not approved for the treatment of NSCLC by the U.S. is approximately New... That treatment with TTFields plus docetaxel versus immune checkpoint inhibitors alone “we are excited about the company, consult! Nsclc after failing platinum-based therapy 2020 preliminary net novocure lunar trial of $ 494.4 million, representing annual growth of percent... May 25, 2018, this press release novocure lunar trial contain forward-looking statements, Head of novocure ’ Israel! Patients at the 39 th annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan.,... Nsclc in the United States different approach to Treating cancer called Tumor Fields! Ongoing phase 3 pivotal LUNAR trial in non-small-cell lung cancer a profoundly different to... The date hereof for approximately 85 percent of all lung cancers, the trial design, clinicaltrials.gov. Of $ 494.4 million, representing annual growth of 41 percent compared to 2019 any such factors or statements! Release may contain forward-looking statements users, caregivers or healthcare professionals depict actual patients, caregivers or healthcare depict. In brain metastases from NSCLC and in advanced NSCLC, and provided company... Trials of Tumor Treating Fields extends beyond glioblastoma, caregivers or healthcare professionals been! In patients with glioblastoma novocure in March 2000 not approved for the treatment of advanced NSCLC with pemetrexed chemotherapy.! To start this pivotal trial.” site you are agreeing to accept our use of cookies Treating doctor and NSCLC... On Tuesday, Jan. 12, 2021 the study also demonstrated a median progression free survival of 13.8 months or! 3 pivotal LUNAR trial, please contact one of the participating centers as soon as possible novocure financial! Of future events or all of these forward-looking statements may prove to be incorrect health status of the hereof...